The New Sofar, S.P.A Holding in Transenterix Inc (NYSEMKT:TRXC)
Sofar, S.P.A filed with the SEC SC 13Dform for Transenterix Inc. The form can be accessed here: 000119312515334084. As reported in Sofar, S.P.A’s form, the filler as of late owns 15.5% or 15,543,413 shares of the Health Care-company.
Transenterix Inc (NYSEMKT:TRXC) stake is a new one for the and it was filed because of activity on September21, 2015. We feel this shows Sofar, S.P.A’s positive view for the stock.
Reasons Why Sofar, S.P.A Bought - Transenterix Inc Stock
Item4. Purpose of Transaction
The description setforth in Item6 of this Schedule 13D is incorporated herein by reference. The Investor acquired such securities in the Company for investment purposes.
Transenterix Inc Institutional Sentiment
Latest Security and Exchange filings show 50 investors own Transenterix Inc. The institutional ownership in Q1 2015 is high, at 33.82% of the outstanding shares. This is increased by 13897 the total institutional shares. 28594029 were the shares owned by these institutional investors. In total 6 funds opened new Transenterix Inc stakes, 17 increased stakes. There were 4 that closed positions and 13 reduced them.
2 managers had the stock in their top Ten. Notable investors are: Stepstone Group Lp, Sv Life Sciences Advisers Llc..
Pura Vida Investments Llc is an institutional investor bullish on Transenterix Inc, owning 262000 shares as of Q1 2015 for 0.40% of its portfolio. Dennis Purcell Aisling Capital Llc owns 8335819 shares or 3.20% of its portfolio. CA Stepstone Group Lp have 2.91% of their stock portfolio for 3480512 shares. Further, Sv Life Sciences Advisers Llc reported stake worth 7.31% of its US stock portfolio. The NC Franklin Street Advisors Inc owns 24100 shares. Transenterix Inc is 0.01% of the manager’s US portfolio.
Business Profile
TransEnterix, Inc. is a medical device company focused on the development and commercialization of a robotic assisted surgical system called the SurgiBot System (the SurgiBot System). The Company’s SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon with robotic assistance while the surgeon remains patientside within the sterile field. It has commercialized the SPIDER Surgical System, (the SPIDER System) a manual laparoscopic system in the United States, Europe and the Middle East. The SPIDER System utilizes flexible instruments and articulating channels that are controlled directly by the surgeon, allowing for multiple instruments to be introduced through a single site. It also offers Flex Ligating Shears (FLS) which is an energy device used with the existing SPIDER Surgical System. The FLS device is designed to deliver controlled energy to ligate and divide tissue.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
